ICMC: Initiative for Certification of Manufacturing Capabilities
Dark Horse Consulting Launches Initiative for Certification of Manufacturing Capabilities
07 oct. 2024 07h58 HE | Dark Horse Consulting Group
Dark Horse Consulting Group, leading cell and gene therapy consultancy, today unveils the Initiative for Certification of Manufacturing Capabilities: ICMC™
The Dark Horse Consulting Group logo contains the initials DHC, rendered in British Racing Green and with a profile of a horse's head within the "D"
Dark Horse Consulting Group Acquires BioTechLogic, Inc.
03 oct. 2024 11h18 HE | Dark Horse Consulting Group
Dark Horse Consulting Group, the global leader in cell and gene therapy consulting, is delighted to announce the acquisition of BioTechLogic, Inc.
ClearPoint-13169-Final-Logo-CMYK jpg.jpg
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial
20 juin 2024 08h45 HE | ClearPoint Neuro, Inc.
ClearPoint® Navigation System to be used for all enrolled patients in Aspen's ASPIRO Parkinson's cell therapy clinical trial
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting
15 avr. 2024 08h00 HE | Neurona Therapeutics
NRTX-1001 administration has been well-tolerated in all individuals treated to date 4 of 5 subjects treated with the lower dose of NRTX-1001 report >50% seizure reduction 3 of 5 subjects report...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
13 mars 2024 07h00 HE | BioCardia, Inc.
BioCardia & StemCardia biotechnology company partnership targets heart failure, the leading cause of death and a condition with limited treatment options
SentiBioLogo.jpg
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
05 janv. 2024 16h05 HE | Senti Biosciences, Inc.
– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024...
2018_DHC_logo_Color_Large.jpg
Dark Horse Consulting Group Announces Launching of DHC Asia Pacific, Hiring of John Ng as General Manager
13 nov. 2023 16h20 HE | Dark Horse Consulting Group
Dark Horse Consulting Group Announces Launching of DHC Asia Pacific, Hiring of John Ng as General Manager
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II
11 oct. 2023 06h00 HE | BioCardia, Inc.
SUNNYVALE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease,...
SentiBioLogo.jpg
Senti Bio to Participate in Upcoming Investor Conferences
05 sept. 2023 08h30 HE | Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies...
SentiBioLogo.jpg
Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates
11 août 2023 08h35 HE | Senti Biosciences, Inc.
– GeneFab transaction provides access to clinical manufacturing and extends cash runway into Q4 2024 – – IND for SENTI-202, potentially the first Logic Gated CAR-NK treatment for AML, on...